Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China Biologic Products has received approval from the Bureau of Health in Guangxi Province to relocate its Fang Cheng plasma collection station to a more favorable location with a wider coverage area and to purchase excess clinical plasma from six other central plasma stations in Guangxi.
Subscribe to our email newsletter
As a result of the approval, the company may relocate the Fang Cheng plasma collection station elsewhere within Fang Cheng Gang City, or within Qin Zhou City or Bei Hai City. Management has started the search and evaluation process in order to find the best location for the station. Management expects that relocating the station would greatly increase the station’s plasma collection volume in the future.
With the approval to buy excess clinical plasma, China Biologic Products (CBP) can now purchase excess clinical plasma from the central plasma stations in six cities of Guangxi Province, including Bai Se, Yu Lin, Lai Bin, Qin Zhou, Fang Cheng Gang and He Zhou. To date, the company has signed contracts with four of these six stations and has procured three tons of excess clinical plasma.
Stanley Wong, CEO of China Biologic, said: “We are pleased to receive the approval from the Bureau of Health in Guangxi Province. It is very helpful to expand our plasma supply. We will continue our efforts to secure the plasma supply for our future growth.”